Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
Reply, specialises in the design and implementation of solutions based on new communication channels and digital media, announces Breed Reply (www.breedreply.com), a new Reply advanced incubator for funding, accelerating and supporting the growth and establishment of ideas and start-ups around the Internet of Things (IoT) across Europe and the USA.
Breed Reply has already been active in setting up a growth project with Xmetrics (www.swim-xmetrics.com), a company that offers an innovative device for swimmers. Xmetrics uses sensors, electronic components and software via mobile devices, to enhance the training sessions of professional and amateur swimmers, analysing their main biometric parameters and their real time performance. Breed Reply has signed a "term sheet" for an investment of £675,000 for , 30% of XMetrics.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762565-reply-launches-breed-funding/
Syneron Medical Ltd. (NASDAQ:ELOS), a leading global aesthetic device company, announced today the international launch of the new PicoWay™ picosecond device at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands, October 8-12, 2014. PicoWay is a state-of-the-art dual wavelength device, with 532nm and 1064nm wavelengths, which utilizes proprietary PicoWay technology to generate picosecond pulses for the treatment of pigmented lesions and tattoos, including recalcitrant tattoos. The staged launch of PicoWay begins in the international market during October 2014 and will continue in the United States in the first half of 2015.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
PicoWay incorporates the highest peak power and the shortest pulse durations of any aesthetic laser in the market. The combination of these two technological breakthroughs creates the strongest photo-mechanical impact, which enables the most safe and effective fracturing of tattoo ink or pigmentation. The revolutionary PicoWay technology is integrated into a proven, reliable Candela™ platform which ensures superior performance and low cost of ownership.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi–phased approach, the tests would be developed for Abbott’s i–STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members.1 With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7293951-abbott-u-s-department-of-defense-develop-portable-blood-tests-concussions/
Sling Media, Inc., a wholly owned subsidiary of EchoStar Corporation (NASDAQ: SATS), today announced the Slingbox® M1 and SlingTV™, replacing the popular and award-winning Slingbox 350 and 500 models. Both of these retail products are the only solutions capable of delivering a customer’s pay TV channels and programs (live or recorded) from the living room to the most popular mobile devices in up to HD quality with no restrictions. In addition SlingTV delivers the power of a Slingbox combined with new “Smarter TV” features designed to enhance the TV viewing experience in the living room.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7272751-slingbox-m1-slingtv-tv-anywhere-mobile-device-smart-living-room-tv-experience/
Today, WebMD Health Corp. (NASDAQ: WBMD) launched WebMD Healthy Target, an integrated health improvement program that uses biometric device data from activity trackers, wireless scales and glucose meters to deliver tailored, physician-reviewed, contextually relevant content and motivational tips to individuals looking to develop sustainable health-conscious habits. WebMD Healthy Target will provide valuable assistance to individuals looking to manage chronic conditions like Type 2 diabetes and obesity, as well as to a broader audience interested in achieving their fitness goals or more generally living a healthier lifestyle.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/70402510-webmd-launches-health-improvement-program-for-iphone/
NI (Nasdaq: NATI) today announced VirtualBench, an all-in-one instrument that integrates a mixed-signal oscilloscope, function generator, digital multimeter, programmable DC power supply and digital I/O. Users interact with VirtualBench through software applications that run on PCs or iPads. The device provides the most common functionality affordably and opens up new possibilities for how engineers can use benchtop instruments.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7230751-ni-reshapes-instrumentation-with-software-based-device-virtualbench
While many of us associate hearing aids with our grandfather sitting in a rocking chair trying to adjust the sound levels, today’s high-tech hearing aids are wireless, virtually undetectable and now for the first time, can be controlled right through your iPhone.
Beltone, one of the world’s largest manufacturers of hearing devices, recently announced the first–ever ‘Made for iPhone’ hearing aid – Beltone First. The ground–breaking device with iPhone capabilities allows consumers to receive clear, clean sound streamed directly from an iPhone, iPad or iPod touch.
To view the multimedia news release, go to: http://www.multivu.com/mnr/7213351-beltone-better-hearing-and-speech-month-iphone-hearing-aid-s
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
In my last blog entry, I covered the announcement of the IBM Watson Mobile Developer Challenge. The Watson Mobile Developer Challenge is designed to catalyze mobile developers to explore the opportunity around mobile cognitive computing - bringing the power of Watson to a smartphone or other mobile device. Entrants submit proposals for mobile apps, and the finalists - to be announced at IBM Impact 2014 - will receive access to IBM Interactive Studios experts and Watson APIs in order to bring their vision to reality.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7167051-ibm-watson-mobile-developer-challenge
